Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE

The Journal of clinical endocrinology and metabolism27 Dec 2006Cited by 152 (Europe PMC)

PMID17192294DOI10.1210/jc.2006-1610PepBankPUB-17192294

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with severe IGF-I deficiency, rhIGF-I increased mean height velocity from 2.8 to 8.0 cm/yr during the first year.
In plain wordsIn children with severe IGF-I deficiency, rhIGF-I increased growth speed from baseline during the first year.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseFirst-year height velocity
Study
n = 76
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60-120 microg/kg twice daily · subcutaneous · first year of treatmentAs given in this study (human).
Measurements
Height velocity at baseline
2.8 cm/yr
average at baseline
Height velocity during first year of treatment
8 cm/yr
first year of treatment
P value for height velocity increase
< 0.0001 p value
first year of rhIGF-I treatment versus baseline
Source sentences
Summary
Height velocity increased from 2.8 cm/yr on average at baseline to 8.0 cm/yr during the first year of treatment (P < 0.0001) and was dependent on the dose administered.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-six children with IGF-I deficiency due to GH insensitivity were treated with rhIGF-I for up to 12 yr under a predominantly open-label design.
Summary · context
rhIGF-I was administered sc in doses between 60 and 120 microg/kg twice daily.
Report a problemFND-1719229401
02HumanNon-randomized trialSafety outcome
In children treated with rhIGF-I, 49% reported hypoglycemia, which also occurred before therapy.
In plain wordsIn children receiving rhIGF-I, low blood sugar occurred before and during therapy.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableHypoglycemia
Study
n = 76
Outcome group
Adverse events · Metabolic and weight
Studied dose
60-120 microg/kg twice daily · subcutaneous · up to 12 yrAs given in this study (human).
Measurements
Subjects reporting hypoglycemia
49%
treated subjects
Source sentences
Summary
The most common adverse event was hypoglycemia, which was observed both before and during therapy. It was reported by 49% of treated subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-six children with IGF-I deficiency due to GH insensitivity were treated with rhIGF-I for up to 12 yr under a predominantly open-label design.
Summary · context
rhIGF-I was administered sc in doses between 60 and 120 microg/kg twice daily.
Report a problemFND-1719229403
03HumanNon-randomized trialSafety outcome
In children receiving rhIGF-I, injection site lipohypertrophy occurred in 32%.
In plain wordsIn children receiving rhIGF-I, fat tissue enlargement occurred at injection sites.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableInjection site lipohypertrophy
Study
n = 76
Outcome group
Adverse events · Skin and wound
Studied dose
60-120 microg/kg twice daily · subcutaneous · up to 12 yrAs given in this study (human).
Measurements
Subjects with injection site lipohypertrophy
32%
treated subjects
Source sentences
Summary
The next most common adverse events were injection site lipohypertrophy (32%) and tonsillar/adenoidal hypertrophy (22%).
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-six children with IGF-I deficiency due to GH insensitivity were treated with rhIGF-I for up to 12 yr under a predominantly open-label design.
Summary · context
rhIGF-I was administered sc in doses between 60 and 120 microg/kg twice daily.
Report a problemFND-1719229404
04HumanNon-randomized trialSafety outcome
In children receiving rhIGF-I, tonsillar/adenoidal hypertrophy occurred in 22%.
In plain wordsIn children receiving rhIGF-I, enlarged tonsils or adenoids occurred.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableTonsillar/adenoidal hypertrophy
Study
n = 76
Outcome group
Adverse events · Immune and inflammation
Studied dose
60-120 microg/kg twice daily · subcutaneous · up to 12 yrAs given in this study (human).
Measurements
Subjects with tonsillar/adenoidal hypertrophy
22%
treated subjects
Source sentences
Summary
The next most common adverse events were injection site lipohypertrophy (32%) and tonsillar/adenoidal hypertrophy (22%).
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-six children with IGF-I deficiency due to GH insensitivity were treated with rhIGF-I for up to 12 yr under a predominantly open-label design.
Summary · context
rhIGF-I was administered sc in doses between 60 and 120 microg/kg twice daily.
Report a problemFND-1719229405
05HumanNon-randomized trialEfficacy outcome
In children with severe IGF-I deficiency, height velocity remained above baseline for up to 8 yr despite later declines.
In plain wordsIn children with severe IGF-I deficiency, growth speed remained above baseline during later rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseLater height velocity
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60-120 microg/kg twice daily · subcutaneous · up to 12 yrAs given in this study (human).
Source sentences
Summary
Height velocities were lower during subsequent years but remained above baseline for up to 8 yr.
2 context sentences(design, population, supporting numbers)
Summary · context
Seventy-six children with IGF-I deficiency due to GH insensitivity were treated with rhIGF-I for up to 12 yr under a predominantly open-label design.
Summary · context
rhIGF-I was administered sc in doses between 60 and 120 microg/kg twice daily.
Report a problemFND-1719229402

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3Results postedNCT00571727

Long-Term Treatment With rhIGF-1 in GHIS

Ipsenn = 9220 May 1991 to 15 Dec 2011

Growth Hormone Insensitivity Syndrome

Trial page ClinicalTrials.govUpdated 6 Jul 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.